Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bioasis Technologies Inc. BIOAF


Primary Symbol: V.BTI

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Comment by prophetoffactzon Feb 28, 2024 9:37pm
80 Views
Post# 35905426

RE:RE:Why do we still get buying of shares from tine ti time?

RE:RE:Why do we still get buying of shares from tine ti time?

narmac wrote: My understanding is at least one entity is interested in BTI,,,,the question is,,,Does the science actually work??,,,,,I am of the opinion it must have issues, and thats assuming a middleof the road scenario!!,,,,I thinks we were fed bovine excrement the past 10 years on this puppy!!!,,,


One entity could be big if J&J has still been researching the technology.

The S&P Biotech ETF is also up 60% in the last four months and is at multi-year highs. That could provide an opportunity to relaunch. In June BTI said: "The current economic environment and market conditions for small-cap development stage biopharmaceutical companies continue to be very challenging."

 


 

<< Previous
Bullboard Posts
Next >>